Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has signed a Letter of Intent dated January 17, 2022 (the “LOI” ) with Sa...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced the Company’s new registered and records office address, confirmed its management and Board...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") is pleased to announce it has entered into an agreement (the “Agreement” ) with Alumina Partners...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compou...
SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it will develop R-107 for the treatment of persistent pulmonary hypertension ...
SAN FRANCISCO, CA and TORONTO, ON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into a License Amendment dated December 17, 2021 (the “ License A ...
SAN FRANCISCO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the journal Scientific Reports, has published a peer-reviewed article reporting that R-107, t...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...